VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2017 | The impact of antiemetics

Matti Aapro, MD, from the Multidisciplinary Oncology Institute, Genolier, Switzerland, discusses the development of new antiemetics at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. New antiemetics have been developed, for example, NEPA, a combination of an NK receptor antagonist and palonosetron. The development of these will have a big impact on the quality of life of patients.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter